AMA Issues CPT Code for bioAffinity Technologies' CyPath Lung Test for Early-Stage Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
The American Medical Association (AMA) has issued a Current Procedural Terminology (CPT) code for bioAffinity Technologies' CyPath Lung, a noninvasive test for early-stage lung cancer. This could potentially increase the usage and adoption of the test.
July 12, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The issuance of a CPT code by the AMA for bioAffinity's CyPath Lung test could potentially increase its usage and adoption, positively impacting the company's revenues.
The issuance of a CPT code by the AMA is a significant step as it allows for the standardized coding and billing of the CyPath Lung test. This could lead to increased usage and adoption of the test by healthcare providers, potentially leading to increased revenues for bioAffinity Technologies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100